BNT327, a bispecific antibody candidate under development by BioNTech (NASDAQ:BNTX) that is seen as critical to the biotech's future success, will compete favorably against rival Summit ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on BioNTech BNTX in the last three months. The table below summarizes their recent ratings ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on BioNTech (NASDAQ:BNTX) in the last three months. The table below summarizes their recent ...

Moderna is suing Pfizer and BioNTech, accusing the companies of infringing on Moderna’s patents when they partnered to develop their own COVID-19 vaccine. Moderna is suing Pfizer and BioNTech ...

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other growth stocks. The market closed last week mostly lower, however, the S&P 500 has been up ...

Cambridge is set to become home to a major new research and development hub as part of a £1bn UK investment by biopharmaceutical firm BioNTech, expected to create more than 400 highly skilled jobs.

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Britain could become the global “superpower” at treating disease, the Government says. The UK will today sign a new billion pound deal with drugmaker BioNTech to pioneer mRNA technology to ...